Balsalazide
 |
|
|---|---|
| Systematic (IUPAC) name | |
| (E)-5-([4-(2-carboxyethylcarbamoyl)phenyl]diazenyl)-2-hydroxybenzoic acid | |
| Clinical data | |
| Trade names | Colazal |
| AHFS/Drugs.com | monograph |
| MedlinePlus | a699052 |
| Pregnancy cat. | B (US) |
| Legal status | POM (UK) |
| Pharmacokinetic data | |
| Bioavailability | <1% |
| Protein binding | ≥99% |
| Half-life | 12hr |
| Identifiers | |
| CAS number | 80573-04-2  |
| ATC code | A07EC04 |
| PubChem | CID 5362070 |
| DrugBank | APRD00141 |
| ChemSpider | 10662422 |
| UNII | P80AL8J7ZP |
| ChEBI | CHEBI:267413 |
| ChEMBL | CHEMBL102265  |
| Chemical data | |
| Formula | C17H15N3O6 |
| Mol. mass | 357.318 g/mol |
| SMILES | eMolecules & PubChem |
|
|
 (what is this?) (verify) |
|
Balsalazide is an anti-inflammatory drug used in the treatment of inflammatory bowel disease. It is sold under the name "Colazal" in the US and "Colazide" in the UK. It is also sold in generic form in the US by several generic manufacturers.
It is usually administered as the disodium salt.
Balsalazide releases mesalazine, also known as 5-aminosalicylic acid, or 5-ASA,[1] in the large intestine. Its advantage over that drug in the treatment of ulcerative colitis is believed to be the delivery of the active agent past the small intestine to the large intestine, the active site of ulcerative colitis.
[edit] References
- ^ Kruis, W.; Schreiber, I.; Theuer; Brandes; Schütz; Howaldt; Krakamp; Hämling et al (2001). "Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses". Gut 49 (6): 783–789. doi:10.1136/gut.49.6.783. PMC 1728533. PMID 11709512. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1728533.
|
||||||||||||||||||||||||||||
